GT Biopharma, Inc.
Returns on Capital
| Fiscal Year | ROE | ROI | ROA |
|---|---|---|---|
| FY2016 | -51.6% | -51.6% | 39,072.0% |
| FY2017 | -57.3% | -57.3% | -56.7% |
| FY2018 | -2,279.6% | -2,279.6% | -1,020.5% |
| FY2019 | 200.1% | 200.1% | -9,759.3% |
| FY2020 | 96.1% | 96.1% | -499.8% |
| FY2021 | -264.8% | -264.8% | -180.3% |
| FY2022 | -178.0% | -178.0% | -124.8% |
| FY2023 | -101.6% | -101.6% | -53.8% |
| FY2024 | 788.1% | 788.1% | -311.0% |
| FY2025 | -490.0% | -490.0% | -349.8% |